We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
+12.33%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$514M
AUM Growth
+$109M
Cap. Flow
+$78.7M
Cap. Flow %
15.3%
Top 10 Hldgs %
96.45%
Holding
21
New
2
Increased
3
Reduced
1
Closed
4

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$89.1M
2
PCRX icon
Pacira BioSciences
PCRX
+$8.62M
3
ARRY
Array Biopharma Inc
ARRY
+$3.19M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$1.77M
5
AEGR
Aegerion Pharmaceuticals
AEGR
+$301K

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$19.8M
2
KIN
Kindred Biosciences, Inc.
KIN
+$3.58M
3
RPRX
Repros Therapeutics Inc.
RPRX
+$422K
4
GYRE icon
Gyre Therapeutics
GYRE
+$419K
5
CARM
Carisma Therapeutics
CARM
+$99K

Sector Composition

Rank Sector Weight
1 Healthcare 88.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
1
Biogen
BIIB
$30B
$95M 18.46%
+310,000
New +$89.1M
ABBV icon
2
AbbVie
ABBV
$443B
$93.6M 18.2%
1,580,000
– –
ARIA
3
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$80.3M 15.61%
12,850,000
– –
MDCO
4
DELISTED
Medicines Co
MDCO
$58.5M 11.38%
1,567,000
– –
DGX icon
5
Quest Diagnostics
DGX
$25.7B
$40.9M 7.95%
575,000
– –
PCRX icon
6
Pacira BioSciences
PCRX
$1.04B
$40.9M 7.95%
532,200
+152,200
+40% +$8.62M
ITCI
7
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$36.3M 7.06%
675,000
+35,000
+5% +$1.77M
AEGR
8
DELISTED
Aegerion Pharmaceuticals
AEGR
$26.1M 5.07%
2,580,000
+25,000
+1% +$301K
AMGN icon
9
Amgen
AMGN
$208B
$14.6M 2.84%
90,000
– –
ESPR
10
DELISTED
Esperion Therapeutics
ESPR
$9.97M 1.94%
448,000
– –
SEEL
11
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$6.46M 1.26%
6
– –
ARRY
12
DELISTED
Array Biopharma Inc
ARRY
$2.95M 0.57%
+700,000
New +$3.19M
AVEO
13
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$2.92M 0.57%
231,376
– –
VVUS
14
DELISTED
Vivus Inc
VVUS
$2.63M 0.51%
257,394
– –
ANIP icon
15
ANI Pharmaceuticals
ANIP
$1.8B
$1.4M 0.27%
31,000
– –
RPRX
16
DELISTED
Repros Therapeutics Inc.
RPRX
$1.21M 0.24%
1,001,000
-131,367
-12% -$422K
CARM
17
DELISTED
Carisma Therapeutics
CARM
– –
-2,060
Closed -$99K
GYRE icon
18
Gyre Therapeutics
GYRE
$641M
– –
-800
Closed -$419K
MRK icon
19
Merck
MRK
$322B
– –
-419,200
Closed -$19.8M
KIN
20
DELISTED
Kindred Biosciences, Inc.
KIN
– –
-689,091
Closed -$3.58M

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q4 2015 Portfolio in Review

As of Q4 2015, Sarissa Capital Management held 21 positions worth $514M, up 27% from $405M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Sarissa Capital Management deployed $78.7M of net new capital in Q4 2015, opening 2 new positions and adding to 3 existing holdings. Its largest new stake was Biogen: 310,000 shares worth $95M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 84% a quarter earlier.

On the sell side, the largest reduction was Repros Therapeutics Inc., an estimated $422K trimmed.

  • Sarissa Capital Management's largest Q4 2015 buy was Biogen: 310,000 shares worth $95M.
  • Sarissa Capital Management added most to Pacira BioSciences in Q4 2015, an estimated $8.62M increase.
  • Sarissa Capital Management's biggest Q4 2015 reduction was Repros Therapeutics Inc., cutting an estimated $422K.
  • Sarissa Capital Management fully exited Merck in Q4 2015, selling an estimated $19.8M.
  • Sarissa Capital Management's ten largest holdings make up 96% of its $514M portfolio in Q4 2015.
  • Sarissa Capital Management opened 2 new positions and closed 4 in Q4 2015.
  • Sarissa Capital Management's portfolio value rose 27% quarter-over-quarter to $514M.

Based on Sarissa Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.